Harvard Bioscience, Inc. Stock Analysis & AI Score
Harvard Bioscience, Inc. (HBIO) has an ST Score of 49.2 (C+), driven by its Forecast (A) and held back by its Financial Strength (D-). Analysts rate it Buy with a $38.00 price target (+373.8% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Medical - Instruments & Supplies |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Harvard Bioscience, Inc. (HBIO) has an ST Score of 49.2 (C+), driven by its Forecast (A) and held back by its Financial Strength (D-). Analysts rate it Buy with a $38.00 price target (+373.8% upside).
- Strongest
- ForecastA
- Weakest
- Financial StrengthD-
All factor grades
- ForecastA
- MomentumA-
- ValuationB+
- GrowthD+
- ProfitabilityD
- Financial StrengthD-
- Piotroski5/9
Contact
HBIO stock: frequently asked questions
What is HBIO's ST Score?
Harvard Bioscience, Inc. (HBIO) has an ST Score of 49.2 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is HBIO a buy, hold, or sell?
Analysts rate HBIO a Buy, with a price target of $38.00 (+373.8% vs the current price). Our ST Score grades it C+ (49.2/100). The ST Score is a data-driven signal, not a recommendation.
What are HBIO's factor grades?
Valuation B+, Profitability D, Financial Strength D-, Momentum A-, Growth D+, Forecast A.
What is HBIO's valuation grade?
Harvard Bioscience, Inc. (HBIO) earns a valuation grade of B+, measured against Medical - Instruments & Supplies peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is HBIO's growth grade?
Harvard Bioscience, Inc. (HBIO) earns a growth grade of D+, measured against Medical - Instruments & Supplies peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is HBIO's profitability grade?
Harvard Bioscience, Inc. (HBIO) earns a profitability grade of D, measured against Medical - Instruments & Supplies peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is HBIO's financial strength grade?
Harvard Bioscience, Inc. (HBIO) earns a financial strength grade of D-, measured against Medical - Instruments & Supplies peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for HBIO?
The average analyst price target for Harvard Bioscience, Inc. (HBIO) is $38.00 from 5 analysts, which is +373.8% versus the recent price of $8.02.
What is HBIO's Piotroski score?
Harvard Bioscience, Inc. (HBIO) has a Piotroski F-Score of 5 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.